Hyperbilirubinemia in the early phase after allogeneic hematopoietic SCT (HSCT) is due to various causes. One of the most important causes of hyperbilirubinemia is veno-occlusive disease/sinusoidal obstructive syndrome (VOD/SOS). However, the prognosis of patients who are clinically diagnosed as SOS varies. We retrospectively evaluated 82 patients who underwent their first allogeneic HSCT. GVHD prophylaxis was a combination of short-term MTX and CsA (n ¼ 77) or tacrolimus (n ¼ 5). Thirty-three patients developed hyperbilirubinemia, with a bilirubin level of at least 2 mg/dL, within 20 days after HSCT. Of these patients, 24 were diagnosed as VOD/SOS using the modified Seattle criteria. Twenty-six recovered to a bilirubin level of o2 mg/dL. We focused on the serum alkaline phosphatase/total bilirubin ratio (ALP/TB) at the onset of hyperbilirubinemia and found that it significantly predicted the recovery from hyperbilirubinemia. OS was significantly higher in patients with a lower ALP/TB ratio (P ¼ 0.00056). In addition, a lower ALP/TB ratio was associated with better survival even in patients who were clinically diagnosed as SOS (Po0.001). The ALP/TB ratio at the onset of hyperbilirubinemia may be a useful predictor for the prognosis of hyperbilirubinemia and SOS early after HSCT.
INTRODUCTION
Hyperbilirubinemia in the early phase after allogeneic hematopoietic SCT (HSCT) has various causes such as infections, GVHD, hepatic veno-occlusive disease/ sinusoidal obstructive syndrome (VOD/SOS), iron overload, calcineurin inhibitors, other drugs, including those used in the conditioning regimens, and so on. 1 Among these causes, SOS is a potentially fatal complication. SOS is a syndrome that is characterized by hyperbilirubinemia, hepatomegaly, right upper quadrant pain and fluid retention early after allogeneic HSCT. 2 Liver biopsy is required for the pathological diagnosis of SOS, but it is difficult to perform this procedure in allogeneic HSCT recipients with hyperbilirubinemia. Therefore, SOS has been clinically diagnosed according to the Seattle criteria 3 or the Baltimore criteria. 4 Depending on what criteria were used, the incidence of SOS has ranged from 5 to 54% and SOS-related mortality has ranged from 15 to 28%. [3] [4] [5] [6] [7] [8] However, these clinical criteria mainly consist of hyperbilirubinemia and fluid retention, both of which can be observed as adverse effects of CsA. Therefore, patients who are clinically diagnosed as SOS may include those with CsA toxicity, which can be more manageable than SOS. CsA-induced hyperbilirubinemia is characterized by only a minimal elevation in the serum alkaline phosphatase (ALP) level. 9 In this study, therefore, we retrospectively investigated the prognostic significance of the serum ALP/total bilirubin ratio (ALP/TB) at the onset of hyperbilirubinemia in patients with hyperbilirubinemia early after HSCT.
PATIENTS AND METHODS

Study population
The study population consisted of patients who underwent their first allogeneic HSCT between April 2007 and December 2010 at Saitama Medical Center, Jichi Medical University. The patients' data were retrospectively collected from medical records. This retrospective study was approved by the Institutional Review Board of Saitama Medical Center.
Transplantation procedure
Prophylaxis for GVHD consisted of a combination of a calcineurin inhibitor and short-term MTX. With regard to calcineurin inhibitors, we mainly used a continuous infusion of CsA with a target blood level between 450 and 550 ng/mL (CsA500) in standard-risk patients and between 250 and 350 ng/mL (CsA300) in high-risk patients. Standard-risk diseases included acute leukemia in the first or second CR, myelodysplastic syndrome without leukemic transformation, and lymphoma in remission. More advanced diseases were included as high-risk diseases. 10 Only five patients, who were enrolled in a randomized trial to compare CsA and tacrolimus (TAC), received a continuous infusion of TAC with a target level of around 15 ng/mL. 11 MTX was administered at 10 mg/m 2 on day 1 and 7 mg/m 2 on days 3 and 6 in HSCT from an HLA-matched related donor. We added MTX at 7 mg/m 2 on day 11 in HSCT from an HLA-mismatched related donor or an HLA-matched unrelated donor. The doses of MTX were increased to 15 mg/m 2 on day 1 and 10 mg/m 2 on days 3, 6 and 11 in HSCT from an HLA-mismatched unrelated donor.
Definition of VOD/SOS
Hyperbilirubinemia was defined as an elevation of the serum TB level to 2 mg/dL or higher. SOS was diagnosed by the modified Seattle criteria.
Briefly, a diagnosis of SOS was made when at least two of the following three signs were observed without any other evident causes within 20 days after transplantation: hyperbilirubinemia with a serum TB level of at least 2 mg/dL, hepatomegaly with right upper quadrant pain, and sudden increase in body weight of more than 2% of the baseline weight. The severity of SOS was classified into three categories (mild, moderate, and severe). 6 Mild and moderate diseases were defined as those that completely improved without any treatment or with treatment such as diuretics or other medications, respectively. SOS was considered to be severe when the symptoms did not improve by day 100 after HSCT or the patient died because of complications.
Statistical considerations
Fisher's exact test was used to compare categorical variables and Student's t-test was used for continuous variables. A multivariate analysis for categorical variables was performed using logistic regression. OS was estimated according to the Kaplan-Meier method, and was compared among groups with the log-rank test. A multivariate analysis for OS was performed with proportional hazards modeling. The probabilities of nonrelapse mortality and relapse were calculated by treating relapse and death without relapse, respectively, as competing events, and the results were compared using Gray's test. 12 We used the receiver operating characteristic (ROC) curve to determine an appropriate cutoff of the ALP/TB ratio to predict a recovery from hyperbilirubinemia. All statistical analyses were performed with EZR (Saitama Medical Center, Jichi Medical University), which is a graphical user interface for R (The R Foundation for Statistical Computing, version 2.13.0). 13 More precisely, it is a modified version of R commander (version 1.6-3) that includes statistical functions that are frequently used in biostatistics.
RESULTS
Characteristics of the patients
Eighty-two patients with a median age of 44.5 years (range 15-65 years) were included in this study. The patient characteristics are summarized in Table 1 . Underlying diseases included AML (n ¼ 35), ALL (n ¼ 8), CML (n ¼ 3), myelodysplastic syndrome (n ¼ 7), non-Hodgkin's lymphoma (n ¼ 10), adult T-cell leukemia/ lymphoma (n ¼ 8), primary myelofibrosis (n ¼ 1) and aplastic anemia (n ¼ 10). All patients received GVHD prophylaxis with a combination of calcineurin inhibitor (CsA in 77 and TAC in 5) and MTX.
Transplantation outcome Engraftment was achieved in 75 patients (91%), a median of 17 days after HSCT, and grade II-IV acute GVHD was observed in 20 patients (24%), a median of 24.5 days after HSCT (range 9-57). Seventeen patients (21%) had disease relapse, a median of 183 days after HSCT (range 43-828), whereas non-relapse mortality was observed in 16 patients (20%).
Hyperbilirubinemia early after transplantation Thirty-three patients (40%) developed hyperbilirubinemia with a bilirubin level of at least 2 mg/dL within 20 days after HSCT. The median onset of hyperbilirubinemia was day 9 after HSCT (range day À 3 to 20). At the onset of hyperbilirubinemia, the median value of the TB level was 2.42 mg/dL (range 2.00-6.91). The maximum TB level among patients who developed hyperbilirubinemia was 3.75 mg/dL (range 2.02-22.21) in median ( Figure 1 ). With regard to the risk factors for hyperbilirubinemia before HSCT, age (46.7 vs 40.6 years, P ¼ 0.061), TB level (0.63 vs 0.46 mg/dL, P ¼ 0.0061), direct bilirubin level (0.25 vs 0.16 mg/dL, P ¼ 0.0057), and the use of reduced-intensity regimen (52% vs 29%, P ¼ 0.041) were higher (with at least borderline significance) in patients who developed hyperbilirubinemia after HSCT than in those who did not. In a multivariate analysis, age (odds ratio 1.04, 95% confidence interval (CI) 1.00-1.07, P ¼ 0.044) and the direct bilirubin level (odds ratio 283, 95% CI 3.72-2.15 Â 10 4 , P ¼ 0.011) Hyperbilirubinemia in the early phase after allo-HSCTwere identified as significant independent risk factors for the development of hyperbilirubinemia. As shown in Figure 2a , OS was in patients who developed hyperbilirubinemia within 20 days after HSCT was significantly inferior to that in those who did not (40% vs 74% at 2 years, P ¼ 0.0045). The impact of hyperbilirubinemia was statistically significant even after adjusting for age and disease risk by a multivariate analysis (hazard ratio 2.79, 95% CI 1.20-6.45, P ¼ 0.017). There was a significant difference in the incidence of non-relapse mortality (39% vs 9.5% at 2 years, P ¼ 0.0011, Figure 2b ), but the incidence of relapse was similar (25% vs 27% at 2 years, P ¼ 0.93).
Among the 33 patients who developed hyperbilirubinemia within 20 days after HSCT, 26 recovered from hyperbilirubinemia with a TB level below 2 mg/dL. The median duration from the development of hyperbilirubinemia to recovery from hyperbilirubinemia was 5.5 days (range 0-34). With regard to the patient characteristics at the onset of hyperbilirubinemia, the serum ALP level, creatinine level, and the ALP/TB ratio were significantly higher in patients who did not recover from hyperbilirubinemia (Table 2) . In a multivariate analysis, the ALP/TB ratio was the only factor that was significantly associated with recovery from hyperbilirubinemia (odds ratio 0.99, 95% CI 0.97-1.00, P ¼ 0.049).
Impact of the ALP/TB ratio on the prognosis of patients with hyperbilirubinemia We evaluated the clinical significance of the ALP/TB ratio at the onset of hyperbilirubinemia for predicting the clinical outcome using the ROC curve. The area under the ROC curve (0.83) suggested that the ALP/TB ratio could be a useful predictor (Figure 3) . We determined the cutoff of the ALP/TB ratio to be 124 by the ROC curve, which gave a sensitivity and specificity for predicting recovery from hyperbilirubinemia of 85.7 and 84.6%, respectively. Recovery from hyperbilirubinemia was more Figure 3 . ROC curve to evaluate the impact of the serum ALP/TB ratio at the onset of hyperbilirubinemia on recovery from hyperbilirubinemia.
Hyperbilirubinemia in the early phase after allo-HSCT M Ashizawa et al frequently observed in the low ALP/TB ratio group (o124 at the onset of hyperbilirubinemia) than in the high ALP/TB ratio group (X124) (96% vs 40%, P ¼ 0.0012). As shown in Figure 4a , the OS was significantly better in the low ALP/TB ratio group (52% vs 20% at 2 years, P ¼ 0.00056), and this effect was statistically significant after adjusting for age and disease risk by a multivariate analysis (hazard ratio 11.13, 95% CI 2.92-42.5, P ¼ 0.00042). Similarly, the incidence of non-relapse mortality was significantly lower in the low ALP/TB ratio group (20% vs 80% at 1 year, P ¼ 0.00029, Figure 4b ).
Diagnosis of VOD/SOS
Twenty-four patients were clinically diagnosed as SOS according to the modified Seattle criteria. The median onset of SOS was 9.5 days after HSCT (range 1-20). With regard to the severity of SOS, 2, 16 and 6 patients were classified as mild, moderate and severe SOS, respectively. The mean ALP/TB ratios at the development of hyperbilirubinemia were 88.0, 104.6, and 211.0, respectively (P ¼ 0.103). OS was significantly superior in the low ALP/TB ratio group, even when we only considered the 24 patients who met the diagnostic criteria of SOS (72.6% vs 0% at 1 year, Po0.0001, Figure 5 ).
DISCUSSION
There are various causes of hyperbilirubinemia in the early phase after HSCT, and therefore, it is difficult to accurately identify the cause of hyperbilirubinemia at its onset. In the current study, 33 patients (40%) developed hyperbilirubinemia with bilirubin level of at least 2 mg/dL within 20 days after HSCT. Twenty-six patients recovered from hyperbilirubinemia, whereas seven did not. We focused on the ALP/TB ratio, as the increase in the serum ALP level is minimal in patients with CsA liver toxicity. In addition, the hyperbilirubinemia due to CsA can generally be controlled by the reducing the dose of CsA. The ALP/TB ratio at the onset of hyperbilirubinemia was the best predictor of recovery from hyperbilirubinemia. In addition, a low ALP/TB ratio (o124) at the onset of hyperbilirubinemia was associated with significantly superior OS and lower non-relapse mortality. Especially, 70% of the patients with a high ALP/TB ratio died within 2 months due to non-relapse causes. Furthermore, among high ALP/TB ratio patients who were clinically diagnosed as SOS according to the Seattle criteria, the incidence of non-relapse mortality was 86% at 2 months after HSCT. There were several limitations of this study. First, the number of patients was limited. Especially, only six patients received BUcontaining conditioning regimens, and therefore, we could not evaluate the effect of BU on the outcome of hyperbilirubinemia. Second, most patients received CsA as GVHD prophylaxis. Therefore, we could not show whether the ALP/TB ratio is a useful predictor for the outcome of hyperbilirubinemia in patients who receive TAC as GVHD prophylaxis. The validity of the ALP/TB ratio in patients who received a BU-based conditioning regimen or who received TAC should be reevaluated in a different cohort. None of the current patients underwent liver biopsy when they developed hyperbilirubinemia. Therefore, we could not obtain a pathological diagnosis of hyperbilirubinemia. However, in general, an invasive procedure is difficult in patients with hyperbilirubinemia early after HSCT. Therefore, other methods, including mainly imaging studies, such as ultrasonography and magnetic resonance imaging, have been used to clarify the etiology of hyperbilirubinemia. Lassau et al. 14 showed that ultrasonography and Doppler findings correlated with the severity of SOS. In addition, magnetic resonance imaging findings, such as hepatic vein narrowing, periportal cuffing, and so on, may be useful in patients with an inconclusive ultrasonography examination. 15 The combination of these non-invasive imaging studies and the ALP/ TB ratio may more accurately predict the prognosis of patients with hyperbilirubinemia and should be evaluated in the future.
We hypothesized that CsA toxicity is the major cause of hyperbilirubinemia in patients with a low ALP/TB ratio. However, there was no significant difference in the incidence of hyperbilirubinemia or recovery from hyperbilirubinemia between the CsA500 group and CsA300 group (data not shown). Therefore, we could not show a dose-dependent effect of CsA on liver toxicity, although some patients showed an improvement of hyperbilirubinemia simply with a reduction in the dose of CsA. This is probably owing to the fact that patients who were at higher risk of liver toxicity, such as those who were not in remission of leukemia, tended to receive CsA at a lower dose.
In conclusion, the ALP/TB ratio at the onset of hyperbilirubinemia may be a simple and useful predictor of the clinical outcome. However, further studies are required to show whether the ALP/TB ratio could be used in other populations.
